Bertelsmann Investments | New York, 03/11/2025

Bertelsmann Investments Invests In Ataraxis AI

The U.S. start-up specializes in AI cancer diagnostics.

Bertelsmann Investments (BI) has participated in a Series A investment round for the U.S. digital health start-up Ataraxis AI totaling US$ 20.4 million. Besides BI, the round was led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, and existing investors Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers including Mario Schlosser, co-founder and former CEO of Oscar Health, Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMind also participated.

Founded by healthcare experts Jan Witowski and Krzysztof Geras, Ataraxis AI is reshaping cancer diagnostics with a frontier AI foundation model called Kestrel. A clinical study has just confirmed the effectiveness of the first Ataraxis offering, “Ataraxis Breast,” whose breast cancer predictions are 30 percent more accurate than the current standard methods. According to Ataraxis AI, it is on track to launch “Ataraxis Breast” in the U.S. this year. The company intends to use the capital infusion to support the continuing development of its offerings and of next-generation AI foundation models.

“This investment is a testament to the groundbreaking work our team is accomplishing and the immense potential of AI in precision medicine. It also reflects our progress, securing funding just a few months after receiving clinical validation,” said Jan Witowski. He adds that the capital puts the company on track to further accelerate its mission of changing how cancer is treated and ultimately impact at least 50 percent of new cancer cases by 2030.”